Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.

Wyeth is now a wholly owned subsidiary of Pfizer615 enrolled

Overview

To compare the therapeutic and radiographic effects and safety between etanercept, methotrexate, and the etanercept/methotrexate combination in patients with rheumatoid arthritis.

Etanercept is an injection administered under the skin twice weekly. Methotrexate is a tablet to be taken once weekly. Patients will not know which treatment they are on. Patients will need to meet the study criteria to be enrolled in the study and sign an informed consent.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

615

Conditions

Active Rheumatoid Arthritis

Interventions

EtanerceptDRUG

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion: \- Generally healthy of at least 18 years of age with active rheumatoid arthritis. Exclusion: \- A history or presence of clinically important medical disease.

Locations (88)

Outcomes

Primary Outcomes

The objective of this study is to evaluate the therapeutic response including radiographic changes and safety of etanercept alone, methotrexate (MTX) alone, and the combination of etanercept and MTX in patients with rheumatoid arthritis (RA)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

St Leonards, New South Wales, Australia

Unnamed facility

Adelaide, Australia

Unnamed facility

Southport, Australia

Unnamed facility

Vienna, Austria

Unnamed facility

Brussels, Belgium

Unnamed facility

Diepenbeek, Belgium

Unnamed facility

Ghent, Belgium

Unnamed facility

Leuven, Belgium

Unnamed facility

Liège, Belgium

Unnamed facility

Česká Lípa, Czechia

...and 78 more locations